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ABSTRACT

3-Hydroxyanthranilate-3,4-dioxygenase (HAO) is a non-heme iron dependent enzyme
that catalyzes the oxidative ring opening of 3-hydroxyanthranilate (HAA) which is an
intermediate in the kynurenine pathway and its ring opening is the final enzymatic step from
tryptophan to quinolinic acid (QUIN). QUIN functions as an N-methyl-D-aspartate (NMDA)
receptor agonist and elevated brain levels of QUIN have been observed in neurodegenerative
diseases. Reducing QUIN levels is of pharmacological importance. Kinetic and calorimetric
studies were performed on human HAO using UV/Vis spectroscopy and isothermal titration
calorimetry to understand its stability and behavior using its natural substrate (3-HAA) and
neurological inhibitors such as acetylsalicylic acid (aspirin). This study reveals the first analysis
of human HAO and facilitates understanding of its binding dynamics and enzymatic activity
which will later support discovering suitable pharmacological compounds.
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Non-Heme iron enzymes vs. Heme iron enzymes

There are a number of chemical reactions that certain enzymes perform with the
assistance of an organic or inorganic molecule called a prosthetic group, a tightly bound
coenzyme (1). Specifically, organic prosthetic groups may be a vitamin, sugar or lipid.
Moreover, inorganic prosthetic groups can simply be a metal ion. A heme prosthetic group
consists of a protoporphyrin ring and a central iron atom. The central iron (Fe) atom can either be
in the ferrous (Fe2+) or the ferric (Fe3+) oxidation state. The protoporphyrin ring is made up of
four pyrrole rings linked by methine bridges which comprises of four methyl, two vinyl, and two
propionate side chains attached (1). Non-enzymatic and enzymatic proteins that utilize the heme
prosthetic group are called hemoproteins. Hemoproteins are able to conduct various biochemical
functions which includes oxygen transport and storage, gas sensing, electron transfer, and
chemical catalysis. In nature, the usage of heme iron for dioxygen activation and oxygen
insertion into organic substrates is common. For example, enzymatic protein such as tryptophan
2, 3-dioxygenase has the ability to bind to oxygen only when there is a bound prosthetic heme
group present. The iron atom is positioned in the middle of the protoporphyrin, bonded to the
four pyrrole nitrogen atoms. Furthermore, only the ferrous state Fe2+ has the ability to bind to
molecular oxygen which renders ferric state Fe3+ inactive due to its inability to bind. The Fe2+
has the capability to form two additional bonds on each side of the heme plane and these binding
sites are called the fifth and sixth coordination sites (1). Myoglobin, a non-enzymatic protein, its
fifth coordination site is engaged by the imidazole ring of a histidine from within, it is also
known as the proximal histidine. The sixth coordination site is where oxygen binding occurs
within the myoglobin protein. Upon binding oxygen to the sixth coordination site, reassembly of
the electrons within the iron atom allows it to be efficiently smaller, thus promoting its
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movement within the plane of the porphyrin. The three dimensional structure of myoglobin has
shown a significant change when it binds to the iron atom. The interaction between iron and
oxygen in myoglobin is viewed as a composite of resonance structures, one with Fe 2+ and
dioxygen and the other with Fe3+ and superoxide ion (1). Electron transfer from the ferrous ion in
heme to oxygen is a binding parameter which creates a ferric ion and superoxide anion complex.
The distal histidine stabilizes the oxygen complex by donating a hydrogen bond to the oxygen
which prevents the release of superoxide because this can be damaging to biological material.
Hemoglobin is a non-enzymatic hemoprotein that is found in red blood cells and consists of four
myoglobin-like subunits. Specifically, two identical alpha chains and two identical beta chains
are the four different polypeptide chains that give the tetramer composition of hemoglobin. Each
subunit holds a heme prosthetic group that allows for efficient transportation and release for
oxygen molecule throughout the body. Cooperative binding and release of oxygen is the essential
reason why hemoglobin is one of the most important heme-proteins in the body, it delivers 10
times as much oxygen as could be delivered by myoglobin and more than 1.7 times as much as
could be delivered by any non-cooperative protein (1).

Cytochrome P450 and its large family are cysteinato-heme enzymes which contain a
prosthetic group constituted of an (Fe3+) protoporphyrin IX linked to the protein by the sulfur
atom of a proximal cysteine ligand. Consistent with their dioxygen activation, cytochrome P450
natural function is to catalyze the hydroxylation of saturated hydrogen bonds, the epoxidation of
double bonds and the oxidation of aromatics. Cytochrome P450 performs oxidation with use of
molecular oxygen by inserting one of the oxygen atoms into a substrate and reduces the second
oxygen to a water molecule by way of NAD(P)H and a reductase (2). Molecular oxygen by itself
is unreactive toward organic molecules at low temperatures due to high energy barriers (3).

3

Nature has found another route for inserting oxygen atoms into compounds via enzymes which
performs the desired oxidation reaction. Enzymes such as cytochrome P450 are metal-dependent
oxygenases. There are three classes of cytochrome P450. Class I is designated to mammalian
mitochondrial enzymes which are involved in steroid syntheses, furthermore, iron-sulfur cluster
is utilized for the transfer of electrons. Class II refers to mammalian enzymes located in the
endoplasmic reticulum of liver cells, which are involved in drug metabolism and utilizes FAD
and FMN to transfer electrons from NADPH to the monooxygenase protein. Lastly, all
cytochrome P450s are part of a multienzymatic assembly that performs numerous biological
functions. Tryptophan 2,3-dioxygenase (TDO) is a heme-dependent dioxygenase in which it
utilizes a histidine-coordinated iron to facilitate dioxygen activation and oxygen insertion
reactions. TDO plays a significant role in tryptophan metabolism, by employing a b-type ferrous
heme to catalyze the oxidative cleavage of the indole ring of L-tryptophan (L-Trp), converting it
to N-formylkynurenine (NFK) (4-6). TDO is the first enzyme in the kynurenine pathway and
designated as the initial and rate limiting step, furthermore, this is the primary route for L-Trp
degradation in mammals, specifically within the liver organ. Addition to the kynurenine
pathways role in L-Trp degradation, it constitutes the major part of the de novo biosynthesis of
nicotinamide adenine dinucleotide (NAD), a redox cofactor that is essential for life sustainment,
in eukaryotic organisms and in a few bacterial species (7, 8).
Heme systems can be studied spectroscopically due to their intense spectral feature
characteristics of the porphyrin ligand. Hemeproteins electromagnetic properties allows for
easier understanding of catalysis whereas non-heme enzymes become more difficult to study
because they do not exhibit the intense spectral features characteristic of the porphyrin ligand. A
widely used spectroscopic technique for delineating mechanistic properties of heme proteins is
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EPR (Electron Paramagnetic Resonance) spectroscopy. EPR detects species that have unpaired
electrons, this includes free radicals and many transition metals ions. Because of the EPR sample
sensitivity to local environments, it provides information of the molecular structure near the
unpaired electron. An important feature found in heme systems is the π-π* transition
characteristic of the porphyrin ligand when combined with valance state and coordination of the
metal allows for efficient study of the hemeprotein in question (9). However, active sites that are
within a ferrous state are often EPR silent and cannot be investigated through conventional EPR
affiliated techniques. The most popular non-heme proteins Fe2+ active sites are composed of two
His, one monodentate carboxylate, and two to three water ligands (10). In comparison to heme
sites which have the protoporphyrin that has only one axial position for molecular oxygen to
bind and proceed with activation, there are additional and also exchangeable positions that can
facilitate the possibility of substrate and/ or cofactor binding to the ferrous iron and new
coordination modes for oxygen activation observed in the non-heme Fe2+ active sites.
Furthermore, the electronic structure of the non-heme Fe2+ active site can vary greatly due to the
His/carboxylate/H2O ligation as opposed to heme sites, this contributes to why it exhibits limited
π-interactions with iron.

2

Dioxygen activation by Mononuclear Non-Heme enzymes

Mononuclear non-heme iron active sites that require dioxygen activation are prevalent in
many metabolically important reactions, each shows some type of pharmaceutical significance.
The dioxygen activation is quite unique. Dioxygen serves multiple roles that have a strong
impact on aerobic life. Oxidative phosphorylation is facilitated by dioxygen functioning as the
terminal electron acceptor which produces the energy rich molecule ATP that is needed through
a number of metabolic processes. Insertion of the oxygen atom into a number of essential
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biological molecules is another role of the dioxygen molecules serves; steroid hormones,
aromatic amino acids, neurotransmitters, signaling molecules, and regulatory factors require
dioxygen to be formed (16).
Dioxygen is a stable molecule with a high potential reactivity which makes it the
desirable reagent that so many biological systems use. Its molecular structure, triplet ground state
of dioxygen is the product two unpaired electrons in degenerate molecular orbitals makes the
direct reaction with singlet molecules which is the spin-paired state of most potential reaction
partners a unfavorable process (18). The understanding of how oxygen activation is conducted is
relevant to number of areas in medical and industry field. Living in a sea of oxygen that is part of
various biological reactions promotes inquiry to how the dioxygen is activated and incorporates
the oxygen atom into these molecules. This information can be advantageous to developing new
compounds that can combat variety of diseases and aid in cultivation of new biofuels that can be
essential to the environment.

Oxidase and oxygenase enzymes activates dioxygen from its common triplet ground state
to the reactive singlet or doublet species. These reactions are dependent on the specific
arrangement or orientation of the insertion molecule reacting with oxygen. Generally, enzymes
are aided by transition metals such iron, copper, or manganese and even organic cofactors such
as heme molecules. The advance in biophysical instruments allows for further understanding of
the activation of biological oxygen activation through the systematic use of computation,
spectroscopic, and structural techniques (19). Oxygen-activating enzymes with mononuclear
non-heme iron active sites are prevalent in the environment, pharmaceutical development, and
medical field due to the fact they participate in metabolically important reactions. Every
mononuclear non-heme iron enzyme is functionally and geometrically unique to each other due
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to their different requirements for activity, various endogenous ligand set, and their coordination
and geometry differ across the spectrum. For example, lipoxygenase requires Fe(III) to be active
and holds 3 histidines, 1 isoleucine bound to carboxylate group, and asparagine for its
endogenous ligand set (21). Lipoxygenases are responsible for oxidizing unsaturated fatty acids
into precursors of ketotrienes and lipoxins, potential targets for anti-inflammatory drugs.
Dioxygen activation is specific to the mononuclear non-heme iron being used and results in
various but similar reaction mechanisms for this group.

3

Extradiol catecholic dioxygenases

Catechol dioxygenases are responsible for nature’s ability to degrade aromatic molecules
in the environment, moreover, the transformation from aromatics into aliphatic products is
considered the last step in this degradation process. Extradiol catecholic dioxygenases are part of
the catechol dioxygenase family that utilizes an Fe(II) ion for catechol cleavage of aromatic
compounds, while intradiol catecholic dioxygenases utilize an Fe(III) ion for oxidative ring
cleavage (22). Both extradiol and intradiol dioxygenases cleave the aromatic ring by way of
inserting both atoms of dioxygen which produces muconic semialdehyde adducts (23). In recent
years structural evidence shows that the active site is composed of Fe(II) with a 2-His+Asp/Glu
facial triad coordination. During the catalytic process, aromatic compounds has been suggested
to provide the necessary electrons to activate dioxygen due to the simple fact there is no
reductant required for catalysis. The extradiol dioxygenase 2-His+Asp/Glu ligand coordination is
prevalent throughout its family with similar mechanistic approach. Catecholic substrate forms a
chelate complex with the extradiol dioxygenase Fe(II) active site, subsequently binds dioxygen
to an adjacent metal ligand site (24). Substrate and dioxygen are activated in concerted
mechanism by transfer of an electron through the metal cofactor. Alkylperoxo intermediate is
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created due to the enforced geometry of the metal complex, subsequently, Criegee rearrangement
is observed and the alkyperoxo intermediate is broken down to a lactone form. Before the final
product is formed, heterolytic O-O bond cleavage during the catalytic process would be enabled
with the protonation of the oxygen atom bound to the iron by an active site acid mechanism.
Hydrolysis of the lactone is conducted by the remaining oxygen atom from dioxygen that bound
to Fe(II) in the initial catalytic process, which allows for the release of open ring product. This
mechanism was recently highlighted by a review article (25). Support has been derived from the
combination of spectroscopic studies and crystal structures of specific enzymes within the
extradiol dioxygenase family. For example, Brevibacterium fuscum homoprotocatechuate 2,3dioxygenase (HPCD) has been trapped within a single crystal, following this was reacting the
crystals to soak in a substrate analogue, 4-nitrocatechol, in the presence of low concentration of
dioxygen before cryo-freezing (26). In this study, three intermediates were found, specifically in
various subunits of the enzyme HPCD. HPCD is a homotetrameric enzyme which the above
study described one subunit contained the chelated substrate-Fe(II)-O2 complex, this type of side
on configuration places the oxygen in correct alignment for reacting with the specific carbon of
the 4-nitrocatechol. Furthermore, 4-nitrocatechol suggested to transfer electron to the oxygen to
form superoxide which is supported by the long Fe-O bond lengths and its sustained Fe(II) state.
Alkylperoxo intermediate were found in two other subunits of HPCD crystals and Fe(II)-product
complex was found in the fourth subunit of HPCD. Further structural studies within the above
study details the two important residues within the HPCD mechanism, Tyr257 and His200.
Tyr257 primarily role is to draw substrate into the reaction intermediates and His200 performs as
an acid catalyst, ensuring activated oxygen species is unstable which it allows it to utilized in the
catalytic process of HPCD. There are a number of enzymes that have the similar 2-His+Asp/Glu
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binding motif as extradiol catechol dioxygenase, which is essential to oxygen activation and
allows for oxygen insertion. Further studies should focus more on the regulation and
manipulation of the 2-His+Asp/Glu to harness the dioxygen activation power.

4

Kynurenine Pathway: Tryptophan Metabolism

There are 20 amino acids that proteins are composed of, 9 of these amino acids are essential
to the human body due to the inability to synthesize which means external intake is required.
Tryptophan is one of the 9 essential amino acids that is utilized in the biosynthesis of proteins
and serves as a precursor to several neurological compounds. After the initial process of
absorption through the body, tryptophan travels throughout the periphery circulation via bound
to albumin or in its free form, however the two states are in equilibrium but the majority of
tryptophan is bound to albumin (27). Moreover, passing through the blood-brain barrier requires
facilitation with a large neutral amino acid transporter (28). Upon arriving in the central nervous
system, tryptophan acts as a precursor to several metabolic processes such as the kynurenine
pathway and the serotonin pathway. Within the peripheral nervous system and the central
nervous system, 95% of tryptophan is metabolized through the kynurenine pathway (29).
Based on the schematic (Scheme 1) of the kynurenine pathway, tryptophan (L-Trp) is
oxidized by cleavage of the indole ring which is initiated by tryptophan 2, 3-dioxygenase (TDO),
indoleamine 2, 3-dioxygenase 1(IDO-1) or IDO-2 (30-32). All three are identified as rate
limiting enzymes of tryptophan metabolism that produces the N-formyl-L-kynurenine (NFK).
Furthermore, each are induced differently throughout the body, TDO is found in the liver and is
induced by tryptophan or corticosteroids, as opposed to IDO-1 which resides in numerous cells,
including macrophages, microglia, neurons, and astrocytes. (33-35). Furthermore, IDO-1 is
induced by immunological responses or in the presence of cytokines, inflammatory molecules
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and more emphatically response is viewed by interferon gamma (IFN-γ) (36-37). With the
production of N-formyl-L-kynurenine, it’s then converted to L-kynurenine (KYN) by the second
enzyme within the kynurenine pathway, formamidase. L-kynurenine is metabolized by three
different routes within the kynurenine pathway to form kynurenic acid, 3-hydroxy-L-kynurenine,
and anthranilic acid by the function of kynurenine aminotransferase, kynurenine 3monooxygenase, and kynureninase enzymes respectively.

Scheme 1 The Kynurenine pathway is the catabolic processes of L-tryptophan.
Along the pathway, formation of 3-hydroxyanthranilic acid (3-HAA) is produced by
kynureninase from 3-hydroxy-L-kynurenine (3-HK) or by nonspecific hydroxylation of
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anthranilic acid. 3-hydroxy-3,4-dioxygnase converts 3-hydroxyanthranilc acid to 2-amino-3carboxymuconate-semialdehyde (ACMS) which is an unstable compound that non-enzymatically
converts to quinolinic acid (QUIN), a precursor to NAD+ and NADP+, known nicotinamide
cofactors. Lastly, ACMS converts to 2-aminomuconic semialdehyde (2-AMS) by α-amino-βcarboxymuconate-ɛ-semialdehyde decarboxylase, which 2-AMS is converted to picolinic acid
(PIC) via a non-enzymatic process (38).
Quinolinic acid is a structural analogue of neurotransmitters such as glutamate and
aspartate that functions as an agonist to N-methyl-D-aspartate (NMDA) receptors (39).
Excessive activity of the NMDA receptors have been attributed to the activation of the
kynurenine pathway which produces above basal level of quinolinic acid that has been confirmed
to be associated with several neurological diseases such as Alzheimer’s disease, anxiety,
depression, epilepsy, human immunodeficiency virus-associated neurocognitive disorders and
Huntington’s disease (40-42). Quinolinic acid has been located within macrophages, microglia
and dendritic cells when inflammatory conditions in the brain are induced (43). Through in vitro
study, the synthesis of quinolinic acid by CD8 dendritic cells induced apoptosis in Th1 target
cells and quinolinic acid can also selectively inhibited the proliferation of CD4 and CD8 T
lymphocytes and natural killer cells undergoing activation (44, 45). Axon-sparing lesions in rat
models have been induced by the injection of quinolinic acid into discrete areas of the brain (46).
There has been an increasing amount of data in the past half century that continues to support
that quinolinc acid plays a major role in neurological diseases and immunological disorders.
Thus, therapeutic methods should concentrate its effects on inhibiting/ regulating it production.
In the central and peripheral nervous system, quinolinic acid is formed by 3-hydroxyanthranilinc
acid 3,4-dioxygenase (HAO), which catalyzes the oxidative ring opening of the kynurenine
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pathway metabolite 3-hydroxyanthranilinic acid, leading to the unstable intermediate 2-amino-3carboxymuconic semialdehyde (ACMS) (47). Due to ACMS instability, it spontaneously
cyclizes to quinolinic acid, which is then further converted to NAD+. Efforts to regulate the
quinolinic acid levels can be established with detail study of HAO and its mechanistic process of
ACMS production, therapeutically making it a primer pharmacological target.

5

3-Hydroxyanthranilate-3,4-dioxygenase

The final enzymatic step in tryptophan catabolism to quinolinic acid is conducted by 3hydroxy-3,4-dioxygenase (HAO) by catalyzing the oxidative ring opening of 3hydroxyanthranilic acid. The biosynthesis of quinolinic acid demands interest due to its role in
neurological disorders. HAO is a non-heme iron (II)-dependent extradiol dioxygenase that
requires the activation of a dioxygen molecule to perform its catalytic function (49). It has been
well documented that HAO plays a significant role in the kynurenine pathway in tryptophan
metabolism, but HAO has also been found in the prokaryotic 2-nitrobenzoic acid biodegradation
pathway (50). The crystal structure HAO was first determined from Cupriavidu metallidurans,
which elucidated that this enzyme is part of the cupin superfamily (51, 52). The Ealick group
discovered each monomer of HAO contains two iron binding sites which one is responsible for
catalytic function and another resembling a rubredoxin site (51). Furthermore, the active site was
reported to have a complex functionality with residues that play key significant roles in the
catalytic mechanism of HAO: iron binding residues consisted of 2-His-1-carboxylate facial triad
that anchored the catalytic iron, substrate binding residues that consisted of Asn27, Arg99,
Glu110, and oxygen binding residue Arg47, which stabilizes the position of oxygen for Fe-O
bond (51). Rubredoxin site found within HAO crystal structure was 24 angstroms away from the
catalytic iron atom and it is coordinated by sulfur atoms derived from four conserved cysteine
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residues at the C terminus, which forms somewhat tetrahedral FeS4 center (51). The role of the
FeS4 centers has been suggested to function as electron carriers in most catalytic mechanisms
(53).

For some time it has been unclear what role FeS4 plays in HAO activity or even does it
have some significance structurally has been the two questions that many studies couldn’t
answer. Recently it has been discovered that the role of the FeS4 is to function as a “spare tire,”
or an iron reservoir (54). The above study provided theoretical and experimental data to support
once the catalytic iron has been removed by downstream metabolite, intermolecular iron
shuttling from the FeS4 to the active site restores catalytic function within an apoenzyme (54).
The binding affinity of the catalytic and FeS4 site has a binding energy difference of ~10
kcal/mol, based on metal-binding dynamics, redistribution of the iron atom in FeS4 to catalytic
site is confirmed (54).
Human HAO (hHAO) is a monomeric bicupin protein consisting of 280 amino acids and
a molecular weight of 33 kDa. Like many of its members within the HAO family, the enzyme
becomes inactive after purification but activity can be restored through reconstitution/incubation
with Fe2+. hHAO lacks the rubredoxin like site that is so famously known for in prokaryotic
HAO structures (51) (PDB entry 2QNK). Furthermore, its catalytic function has been consistent
with the rest of the HAO family, catalyzing the ring opening of 3-hydroxyanthranilate acid (3HAA) within the kynurenine pathway to facilitate the non-enzymatic production of quinolinic
acid (46). A recent computationally study of hHAO suggests the significance of the Arg43,
Arg95 and Glu105, which are conserved active site residues also found in the bacterial HAO
proteins (55). Another significant fact was the catalytic mechanism proposed by Zhang et al.
coincided with the modeling study, which suggested the reaction to exergonic with the final
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energy of the system to be 59.8 kcal mol-1 lower than the initial and highest energy barriers (55).
The point of this current study is to understand hHAO binding dynamics, its potential inhibition
with known neurological inhibitors, and whether it’s a regulatory site within the kynurenine
pathway.

6

Experimental Data

Chemicals- 3-hydroxyanthranilate acid, picolinic acid, acetylsalicylic acid, ammonium
ferrous sulfate hexahydrate, ascorbate, EDTA, Tris base, and glycerol were purchased from
Sigma at the highest grade available.

Protein Preparation- hHAO plasmid was purchased from DNASU plasmid repository.
Overexpression and protein purification conducted according to a published method (46). All
catalytic activity assays were performed in 50 mM Tris-HCl, pH 7.6, and 5% glycerol. The
metal-free, apo-form of hHAO was prepared by overnight treatment with EDTA (10 mM) at
4°C, followed by dialysis and gel filtration chromatography for removal of EDTA. The fully
iron-loaded hHAO (holo-hHAO) was obtained by adding 2 eq of Fe2+ (from a fresh O2-free
solution of ammonium ferrous sulfate) to apo-hHAO under anaerobic conditions. Excess iron
ions were removed by gel-filtration chromatography using argon-saturated buffer.

Inhibition Assays - The inhibition assays were performed in 50 mM Tris-HCl buffer (pH
7.6, 5% glycerol) as previously described using an Agilent 8453 spectrophotometer. The rate of
enzymatic reactions was monitored based on formation of deoxygenation product, 2-amino-3carboxymuconic semialdehyde (ACMS), at 360 nm ɛ360 nm = 47,500 M-1 cm-1 (46). A typical
reaction mixture consisted of 5-100 µM 3-HAA, fixed concentration of acetylsalicylic acid
(ASA) for each Michaelis-Menten (MM) plot ranging from 50-150 µM, and 500 ng of
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reconstituted hHAO diluted to 500 µL with 50 mM Tris-HCl pH 7.6 buffer. The above procedure
was conducted in the same manner for picolinic acid (PA) at fixed concentration for each MM
plot. For the determination of kinetic parameters, initial rates of product formation were plotted
versus the substrate concentration and fitted to the Michaelis-Menton equation using Origin 8.5.
Competitive, Mixed-typed, and Non-competitive inhibition equations were tested using Origin
8.5 to identify PA and ASA mode of inhibition.

Oxygen Affinity Assay- The activity of hHAO was measured by monitoring the decay of
dioxygen within a finite chamber using a Perspex oxygen electrode. The chamber was saturated
with a specific concentration of O2 ranging from 100-700 µM with a fixed concentration of 100
µM of 3-HAA. Once the chamber was stabilized with the specific O 2 concentration, reconstituted
hHAO was injected into the chamber with a fixed concentration of 1 µg diluted to 1 mL with 50
mM Tris-HCl 7.6 pH buffer. For the determination of kinetic parameters, initial rates of O 2 decay
were plotted versus the O2 concentration and fitted with to a Hill/MM equation using Origin 8.5.

Isothermal Titration Calorimetry Assay- ITC experiments were conducted in an oxygenfree environment and performed at 10°C on a MicroCal VP-ITC. The sample cell contained 20
µM of hHAO with a volume of 1.5 mL using a 10 mM potassium phosphate pH 7.8 5% glycerol
and .01% dimethyl sulfoxide (DMSO). 3-HAA was dissolved in DMSO and diluted to 100 µM
in 280 µL syringe, ASA was also dissolved in DMSO and diluted to 200 µM for the second
assay, and each ligand used the same buffer as the sample cell. The ligand solution was titrated
into the protein solution; 28 injections (10 µL) of 4.8 seconds duration were made at 200 s
intervals. Control experiments of ligand to buffer showed insignificant heats ensuring the DMSO
percentage was matched in both sample cell and syringe. The data were processed and
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thermodynamic parameters obtained by fitting the data to single-site-binding model using Origin
7.0 and fixing the stoichiometry as 1.0 for 1 binding site. All data from ITC measurements are
shown in figures 2 and 3.

7

Results

Inhibition Assay using Acetylsalicylic acid. ASA inhibited the activity in hHAO
production of 3-HAA to ACMS. Various inhibition equations were used for the fitting with
Origin 8.5 (56). The experimental data fit well with both mixed-type and non-competitive
inhibition with an adjusted chi square of .97505 and .97, respectively. The adjusted chi-square
values represents how well the data fits with its respective enzyme inhibition equation.
Ultimately, using ASA as an inhibitor decreases the activity of hHAO significantly with
inhibition constant (Ki) of 168 µM, which is shown in figure 1 and 2.
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Figure 1 Michaelis-Menton plot to the left and Lineweaver-Burk plot in the center.
ASA was fitted to the Mix-type inhibition equation using Origin 8.5 and produced an adjusted
chi-square of .97505. Each color trace represents the fixed concentration that ASA was used to
conduct the assay.
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Figure 2 Michaelis-Menton plot to the left and Lineweaver-Burk plot in the center.
ASA was fitted to the non-competitive inhibition equation using Origin 8.5 and produced an
adjusted chi-square of .97. Each color trace represents the fixed concentration that ASA was used
to conduct the assay.

Inhibition Assay using Picolinic Acid. As evident in Fig. 3, picolinic acid performs as a
competitive inhibitor, which decreases the activity of hHAO significantly. The inhibition
constant is 131 µM bring activity down by 30% when compared to absence of picolinic acid in
the assay. The experimental data was fit with the competitive inhibition equation with a reduced
chi square of .9919.
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Figure 3 The inhibitory effect that Picolinc acid has on hHAO activity is shown in the
Lineweaver-Burk plot and in the Michaelis-Menton plot in right corner. Competitive
inhibition constant was shown to be 131 µM.
Oxygen Affinity Assay. The theoretical Michaelis-Menton constant (Km) for oxygen is
estimated to be 225 µM. hHAO becomes saturated between 400 to 500 µM of oxygen.
Furthermore, the catalytic turnover (Kcat) is calculated to be ~2 per second within this
experiment. Oxygen concentration exceeding 500 µM shows to decrease hHAO activity.
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Figure 4 A spline curve is shown in the Michaelis-Menton plot for O2 affinity at standard
temperature and pressure.
Isothermal Titration Calorimetry Assay. ITC data shows (Fig. 5) that binding of 3-HAA
to hHAO is exergonic process by which producing heat energy of -70 kcal per mol. The N-value
is .966 and C value was calculated as 369 (57). The N value represents the average number of
binding sites per mole of protein in the solution. The C value is the critical parameter that
determines the shape of the binding isotherm and is the product of the binding constant, initial
macromolecule concentration in the cell and the stoichiometry parameter according to MicroCal.
C values between 10 and 500 are considered optimal for determining the accuracy of an
isotherm. The entropy was calculated as -215 cal per mole degree and the equilibrium constant
(KA) was measured as 2.19 x 10-7 M-1
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Figure 5 Shows the isotherm profile of hHAO being titrated with 3-HAA.
Upon the first injection heat is released in the amount of -70 kcal per mol. Saturation begins at 1
molar ratio with a decline in heat production.
Isothermal Titration Assay using Acetylsalicylic Acid hHAO was titrated with ASA
producing heat in the amount of -2 kcal per mol. Saturation begins at .7 molar ratio and
continues until reaching 2.0 molar ratio where it starts to plateau.
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Figure 6 Isotherm profile of hHAO titrated with acetylsalicylic acid shows binding between
the two macromolecules with a ∆H of -2.0 kcal per mol.
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Discussion

Inhibition of hHAO using ASA. Acetylsalicylic acid also known as aspirin, the
nonsteroidal anti-inflammatory drug, has found a new function within this study. Its ability to
reduce hHAO activity has been confirmed. Inhibition constant (Ki) was calculated to be 169 µM.
The non-competitive and mixed-typed inhibition models both fit well with the experimental data.
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ASA has been shown in previous studies to possess antioxidant activity at inhibiting quinolinic
acid induced superoxide anion generation, lipid peroxidation and maintained cell integrity in rat
hippocampus (58). In addition to the oxidative protection, the above study has shown both
acetylsalicylic acid and acetaminophen can inhibit the activity of rat liver HAO individually,
moreover, enzyme activity is reduced by 77% when both compounds are combined the assay
(58). ASA has the ability to bind to iron coordinated complexes such as Fe2+ and Fe3+ (59),
suggesting that its mechanism of inhibition is ligation of the catalytic iron ion within the active
site of HAO enzyme, contributing to the reduced activity in the presence of ASA. The theory of
ASA binding to the active site in some facet is supported by the ITC data in Fig. 5. Once ASA is
injected into the sample cell with hHAO, there is a production of heat in the amount -2 kcal per
mol which indicates binding between the two macromolecules. These findings support further
research into ASA as a scaffold in which new pharmacological compounds can be derived from
to effectively inhibit hHAO activity.

Picolinic acid inhibitory effect. Based on the Fig. 3, picolinic acid has the ability to
inhibit the activity of hHAO. The calculated inhibition constant (Ki) was calculated as 132 µM
during this assay and according to the Lineweaver-Burk plot, picolinic acid performs as
competitive type inhibitor. As a competitive inhibitor, picolinic acid competes for the active site
of hHAO against 3-HAA. Picolinic acid and 3-HAA are very similar in structure and contribute
to the competitive inhibition that is observed in this study. It has been recently discovered that
picolinic acid has the ability to chelate and remove the catalytic iron from a bacterial HAO (54).
The above study suggested that picolinic acid has taken advantage of the HAO active site which
holds two weakly associated water ligands, thus allowing for binding followed by removal of the
catalytic metal (54).
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Picolinic acid is a downstream metabolite within the kynurenine pathway and its
mechanism of inhibition, which effectively chelates and removes catalytic iron from the active
site can be categorized as feedback inhibition. Within the kynurenine pathway, nonenzymatic
cyclization of 2-aminomuconate-6-semialdehyde produces picolinic acid (Scheme 1). Picolinic
acid is a dead end product within the kynurenine pathway and its accumulation will lead to
inhibition of HAO enzyme, which suggests that HAO is a controlled regulatory site within the
kynurenine pathway during high metabolic activity.
hHAO affinity for O2. The Michaelis-Menton (MM) constant (Km) for O2 was measured
at ~150 µM. This was a significant value since oxygen solubility in liquid is 258 µM at standard
temperature and pressure. MM plot shows saturation of hHAO occurring at 470 µM, which is
more than double the Km for this reaction (Figure 4). Furthermore, there is possible substrate
inhibition being seen after O2 concentration exceeds 500 µM. Excess oxygen not being used in
the incorporation can inhibit the activity of hHAO is supported by a previous EPR study where
exposure HAO to oxygen results in metal ion oxidation and enzyme auto-inactivation (60). This
suggests that excess oxygen which is not activated due to saturation of the active site can become
toxic to the catalytic iron and reduce activity of the enzyme.

Binding affinity of 3-hydroxyanthranilic acid. hHAO binding with 3-HAA was observed
in a 1 to 1 ratio and shown in the isotherm profile in (Fig. 5). N value of .966 and C value of 369
(57) indicates that the thermodynamic parameters calculated are in reasonable measure and can
be used to elucidate additional information about the reaction between hHAO and its substrate 3HAA which produces the enzyme-substrate (ES) complex. The equilibrium constant
[E][S]/[ES]= Keq was calculated using Origin 8.5 as 2.19 x 10-7 M-1 With the inversion of Keq,
this produces 1/Keq, which equals the dissociation constant (Kd) of 46 nM. The dissociation
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constant is the value of affinity between enzyme and its substrate without incorporating the
complex rates of various intermediate formations and product release (61). This approach of
viewing Michaelian kinetics allows for the isolation of [E] + [S]  [ES], which can help
elucidate further information into the thermodynamics of hHAO and 3-HAA binding.
Upon hHAO binding to its substrate, there is a release of heat at -70 kcal per mol,
indicating the binding of this reaction is exergonic process (see Fig 5). In addition to the enthalpy
change (∆H) measured at -70 kcal per mol, entropy (∆S) was measured at -215 cal per mol
degree, indicating the degree of freedom has been lost upon binding. Obtaining values of ∆H,
∆S, using the correct gas constant, and using the temperature the reaction was conducted in,
Gibbs free energy (∆G) was calculated at -9.2 kcal per mol.

9

Conclusion

To summarize, on the basis of spectroscopic analysis, this study has suggested the ability
of aspirin to perform as a mixed type inhibitor by chelating the catalytic iron within the active
site inducing inactivation of hHAO. In addition, a downstream metabolite has been found to
inhibit the activity of hHAO by acting as a competitive type inhibitor that performs in similar
action as aspirin, using chelation as a method of inactivation. Aspirin, 3-HAA, and picolinic acid
have similar structures, combining this with the recent data, this warrants investigation into these
inhibitory molecules to which can facilitate innovative neurological therapies that can regulate
hHAO activity in various neurological disorders. Lastly, the binding parameters found within
this study can contribute to the understanding of the reaction mechanism of hHAO. To the best
of my knowledge, this is first time that the binding affinity of hHAO has been reported. Already
this data has affirmed that the rate of catalysis in this reaction is faster than the rate of
dissociation within this reaction due to Km value 20 µM being significantly larger than the Kd 46
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nM, this theory has established by understanding the meaning of these values (61). It is my hope
that further investigation of hHAO is elicited from this study.
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